2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Martin J. van den Bent, MD, presenting abstract LBA2000, Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An intergroup trial during Central Nervous System Tumors Oral Abstract Session

Martin J. van den Bent, MD, presenting abstract LBA2000, Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An intergroup trial during Central Nervous System Tumors Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Martin J. van den Bent, MD, presenting abstract LBA2000, Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An intergroup trial during Central Nervous System Tumors Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org